drug
GIM-531
Phase 2updated 6mo agoby Georgiamune Inc
Phase 2community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying GIM-531
News(1)
- Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B dealGeorgiamune, an immunology-focused biotech out of Maryland, has licensed a preclinical cancer drug candidate to Stemline Therapeutics, owned by Italy's Menarini Group, for up to $1.1 billion.fiercebiotech · 26d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that